Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 53

1.

Receptor activator of nuclear factor kB ligand, osteoprotegerin, and risk of death following a breast cancer diagnosis: results from the EPIC cohort.

Sarink D, Schock H, Johnson T, Chang-Claude J, Overvad K, Olsen A, Tjønneland A, Arveux P, Fournier A, Kvaskoff M, Boeing H, Karakatsani A, Trichopoulou A, La Vecchia C, Masala G, Agnoli C, Panico S, Tumino R, Sacerdote C, van Gils CH, Peeters PHM, Weiderpass E, Agudo A, Rodríguez-Barranco M, Huerta JM, Ardanaz E, Gil L, Kaw KT, Schmidt JA, Dossus L, His M, Aune D, Riboli E, Kaaks R, Fortner RT.

BMC Cancer. 2018 Oct 22;18(1):1010. doi: 10.1186/s12885-018-4887-3.

2.

Ovarian cancer early detection by circulating CA125 in the context of anti-CA125 autoantibody levels: Results from the EPIC cohort.

Fortner RT, Schock H, Le Cornet C, Hüsing A, Vitonis AF, Johnson TS, Fichorova RN, Fashemi T, Yamamoto HS, Tjønneland A, Hansen L, Overvad K, Boutron-Ruault MC, Kvaskoff M, Severi G, Boeing H, Trichopoulou A, Papatesta EM, La Vecchia C, Palli D, Sieri S, Tumino R, Sacerdote C, Mattiello A, Onland-Moret NC, Peeters PH, Bueno-de-Mesquita HBA, Weiderpass E, Quirós JR, Duell EJ, Sánchez MJ, Navarro C, Ardanaz E, Larrañaga N, Nodin B, Jirström K, Idahl A, Lundin E, Khaw KT, Travis RC, Gunter M, Johansson M, Dossus L, Merritt MA, Riboli E, Terry KL, Cramer DW, Kaaks R.

Int J Cancer. 2018 Apr 1;142(7):1355-1360. doi: 10.1002/ijc.31164. Epub 2017 Dec 11.

3.

Anti-Müllerian hormone and risk of ovarian cancer in nine cohorts.

Jung S, Allen N, Arslan AA, Baglietto L, Barricarte A, Brinton LA, Egleston BL, Falk RT, Fortner RT, Helzlsouer KJ, Gao Y, Idahl A, Kaaks R, Krogh V, Merritt MA, Lundin E, Onland-Moret NC, Rinaldi S, Schock H, Shu XO, Sluss PM, Staats PN, Sacerdote C, Travis RC, Tjønneland A, Trichopoulou A, Tworoger SS, Visvanathan K, Weiderpass E, Zeleniuch-Jacquotte A, Dorgan JF.

Int J Cancer. 2018 Jan 15;142(2):262-270. doi: 10.1002/ijc.31058. Epub 2017 Oct 4.

4.

Anti-Mullerian hormone and endometrial cancer: a multi-cohort study.

Fortner RT, Schock H, Jung S, Allen NE, Arslan AA, Brinton LA, Egleston BL, Falk RT, Gunter MJ, Helzlsouer KJ, Idahl A, Johnson TS, Kaaks R, Krogh V, Lundin E, Merritt MA, Navarro C, Onland-Moret NC, Palli D, Shu XO, Sluss PM, Staats PN, Trichopoulou A, Weiderpass E, Zeleniuch-Jacquotte A, Zheng W, Dorgan JF.

Br J Cancer. 2017 Oct 24;117(9):1412-1418. doi: 10.1038/bjc.2017.299. Epub 2017 Sep 5.

5.

A Comparative Study on the WCRF International/University of Bristol Methodology for Systematic Reviews of Mechanisms Underpinning Exposure-Cancer Associations.

Ertaylan G, Le Cornet C, van Roekel EH, Jung AY, Bours MJL, Damms-Machado A, van den Brandt PA, Schock H, de Kok TM, Theys J, Arts ICW, Kaaks R, Weijenberg MP, Fortner RT.

Cancer Epidemiol Biomarkers Prev. 2017 Nov;26(11):1583-1594. doi: 10.1158/1055-9965.EPI-17-0230. Epub 2017 Jul 28. Review.

6.

Early pregnancy sex steroids during primiparous pregnancies and maternal breast cancer: a nested case-control study in the Northern Sweden Maternity Cohort.

Fortner RT, Tolockiene E, Schock H, Oda H, Lakso HÅ, Hallmans G, Kaaks R, Toniolo P, Zeleniuch-Jacquotte A, Grankvist K, Lundin E.

Breast Cancer Res. 2017 Jul 18;19(1):82. doi: 10.1186/s13058-017-0876-8.

7.

Circulating RANKL and RANKL/OPG and Breast Cancer Risk by ER and PR Subtype: Results from the EPIC Cohort.

Sarink D, Schock H, Johnson T, Overvad K, Holm M, Tjønneland A, Boutron-Ruault MC, His M, Kvaskoff M, Boeing H, Lagiou P, Papatesta EM, Trichopoulou A, Palli D, Pala V, Mattiello A, Tumino R, Sacerdote C, Bueno-de-Mesquita HBA, van Gils CH, Peeters PH, Weiderpass E, Agudo A, Sánchez MJ, Chirlaque MD, Ardanaz E, Amiano P, Khaw KT, Travis R, Dossus L, Gunter M, Rinaldi S, Merritt M, Riboli E, Kaaks R, Fortner RT.

Cancer Prev Res (Phila). 2017 Sep;10(9):525-534. doi: 10.1158/1940-6207.CAPR-17-0125. Epub 2017 Jul 12.

8.

Androgens Are Differentially Associated with Ovarian Cancer Subtypes in the Ovarian Cancer Cohort Consortium.

Ose J, Poole EM, Schock H, Lehtinen M, Arslan AA, Zeleniuch-Jacquotte A, Visvanathan K, Helzlsouer K, Buring JE, Lee IM, Tjønneland A, Dossus L, Trichopoulou A, Masala G, Onland-Moret NC, Weiderpass E, Duell EJ, Idahl A, Travis RC, Rinaldi S, Merritt MA, Trabert B, Wentzensen N, Tworoger SS, Kaaks R, Fortner RT.

Cancer Res. 2017 Jul 15;77(14):3951-3960. doi: 10.1158/0008-5472.CAN-16-3322. Epub 2017 Apr 5.

9.

Demographic, lifestyle, and other factors in relation to antimüllerian hormone levels in mostly late premenopausal women.

Jung S, Allen N, Arslan AA, Baglietto L, Brinton LA, Egleston BL, Falk R, Fortner RT, Helzlsouer KJ, Idahl A, Kaaks R, Lundin E, Merritt M, Onland-Moret C, Rinaldi S, Sánchez MJ, Sieri S, Schock H, Shu XO, Sluss PM, Staats PN, Travis RC, Tjønneland A, Trichopoulou A, Tworoger S, Visvanathan K, Krogh V, Weiderpass E, Zeleniuch-Jacquotte A, Zheng W, Dorgan JF.

Fertil Steril. 2017 Apr;107(4):1012-1022.e2. doi: 10.1016/j.fertnstert.2017.02.105.

10.

Correlates of circulating ovarian cancer early detection markers and their contribution to discrimination of early detection models: results from the EPIC cohort.

Fortner RT, Vitonis AF, Schock H, Hüsing A, Johnson T, Fichorova RN, Fashemi T, Yamamoto HS, Tjønneland A, Hansen L, Overvad K, Boutron-Ruault MC, Kvaskoff M, Severi G, Boeing H, Trichopoulou A, Benetou V, La Vecchia C, Palli D, Sieri S, Tumino R, Matullo G, Mattiello A, Onland-Moret NC, Peeters PH, Weiderpass E, Gram IT, Jareid M, Quirós JR, Duell EJ, Sánchez MJ, Chirlaque MD, Ardanaz E, Larrañaga N, Nodin B, Brändstedt J, Idahl A, Khaw KT, Allen N, Gunter M, Johansson M, Dossus L, Merritt MA, Riboli E, Cramer DW, Kaaks R, Terry KL.

J Ovarian Res. 2017 Mar 20;10(1):20. doi: 10.1186/s13048-017-0315-6.

11.

A prospective cohort study of oral contraceptive use and ovarian cancer among women in the United States born from 1947 to 1964.

Shafrir AL, Schock H, Poole EM, Terry KL, Tamimi RM, Hankinson SE, Rosner BA, Tworoger SS.

Cancer Causes Control. 2017 May;28(5):371-383. doi: 10.1007/s10552-017-0876-0. Epub 2017 Mar 13.

12.

Pre-diagnosis insulin-like growth factor-I and risk of epithelial invasive ovarian cancer by histological subtypes: A collaborative re-analysis from the Ovarian Cancer Cohort Consortium.

Ose J, Schock H, Poole EM, Lehtinen M, Visvanathan K, Helzlsouer K, Buring JE, Lee IM, Tjønneland A, Boutron-Ruault MC, Trichopoulou A, Mattiello A, Onland-Moret NC, Weiderpass E, Sánchez MJ, Idahl A, Travis RC, Rinaldi S, Merritt MA, Wentzensen N, Tworoger SS, Kaaks R, Fortner RT.

Cancer Causes Control. 2017 May;28(5):429-435. doi: 10.1007/s10552-017-0852-8. Epub 2017 Feb 16.

13.

Osteoprotegerin and breast cancer risk by hormone receptor subtype: a nested case-control study in the EPIC cohort.

Fortner RT, Sarink D, Schock H, Johnson T, Tjønneland A, Olsen A, Overvad K, Affret A, His M, Boutron-Ruault MC, Boeing H, Trichopoulou A, Naska A, Orfanos P, Palli D, Sieri S, Mattiello A, Tumino R, Ricceri F, Bueno-de-Mesquita HB, Peeters PH, Van Gils CH, Weiderpass E, Lund E, Quirós JR, Agudo A, Sánchez MJ, Chirlaque MD, Ardanaz E, Dorronsoro M, Key T, Khaw KT, Rinaldi S, Dossus L, Gunter M, Merritt MA, Riboli E, Kaaks R.

BMC Med. 2017 Feb 8;15(1):26. doi: 10.1186/s12916-017-0786-8.

14.

Human Chorionic Gonadotropin Does Not Correlate with Risk for Maternal Breast Cancer: Results from the Finnish Maternity Cohort.

Fortner RT, Schock H, Kaaks R, Lehtinen M, Pukkala E, Lakso HÅ, Tanner M, Kallio R, Joensuu H, Korpela J, Toriola AT, Hallmans G, Grankvist K, Zeleniuch-Jacquotte A, Toniolo P, Lundin E, Surcel HM.

Cancer Res. 2017 Jan 1;77(1):134-141. doi: 10.1158/0008-5472.CAN-16-1524. Epub 2016 Oct 26.

15.

Hormone concentrations throughout uncomplicated pregnancies: a longitudinal study.

Schock H, Zeleniuch-Jacquotte A, Lundin E, Grankvist K, Lakso HÅ, Idahl A, Lehtinen M, Surcel HM, Fortner RT.

BMC Pregnancy Childbirth. 2016 Jul 4;16(1):146. doi: 10.1186/s12884-016-0937-5.

16.

A Prospective Evaluation of Early Detection Biomarkers for Ovarian Cancer in the European EPIC Cohort.

Terry KL, Schock H, Fortner RT, Hüsing A, Fichorova RN, Yamamoto HS, Vitonis AF, Johnson T, Overvad K, Tjønneland A, Boutron-Ruault MC, Mesrine S, Severi G, Dossus L, Rinaldi S, Boeing H, Benetou V, Lagiou P, Trichopoulou A, Krogh V, Kuhn E, Panico S, Bueno-de-Mesquita HB, Onland-Moret NC, Peeters PH, Gram IT, Weiderpass E, Duell EJ, Sanchez MJ, Ardanaz E, Etxezarreta N, Navarro C, Idahl A, Lundin E, Jirström K, Manjer J, Wareham NJ, Khaw KT, Byrne KS, Travis RC, Gunter MJ, Merritt MA, Riboli E, Cramer DW, Kaaks R.

Clin Cancer Res. 2016 Sep 15;22(18):4664-75. doi: 10.1158/1078-0432.CCR-16-0316. Epub 2016 Apr 8.

17.

An epidemiological model for prediction of endometrial cancer risk in Europe.

Hüsing A, Dossus L, Ferrari P, Tjønneland A, Hansen L, Fagherazzi G, Baglietto L, Schock H, Chang-Claude J, Boeing H, Steffen A, Trichopoulou A, Bamia C, Katsoulis M, Krogh V, Palli D, Panico S, Onland-Moret NC, Peeters PH, Bueno-de-Mesquita HB, Weiderpass E, Gram IT, Ardanaz E, Obón-Santacana M, Navarro C, Sánchez-Cantalejo E, Etxezarreta N, Allen NE, Khaw KT, Wareham N, Rinaldi S, Romieu I, Merritt MA, Gunter M, Riboli E, Kaaks R.

Eur J Epidemiol. 2016 Jan;31(1):51-60. doi: 10.1007/s10654-015-0030-9. Epub 2015 May 13.

18.

Inflammatory Markers and Risk of Epithelial Ovarian Cancer by Tumor Subtypes: The EPIC Cohort.

Ose J, Schock H, Tjønneland A, Hansen L, Overvad K, Dossus L, Clavel-Chapelon F, Baglietto L, Boeing H, Trichopolou A, Benetou V, Lagiou P, Masala G, Tagliabue G, Tumino R, Sacerdote C, Mattiello A, Bueno-de-Mesquita HB, Peeters PH, Onland-Moret NC, Weiderpass E, Gram IT, Sánchez S, Obon-Santacana M, Sànchez-Pérez MJ, Larrañaga N, Castaño JM, Ardanaz E, Brändstedt J, Lundin E, Idahl A, Travis RC, Khaw KT, Rinaldi S, Romieu I, Merritt MA, Gunter MJ, Riboli E, Kaaks R, Fortner RT.

Cancer Epidemiol Biomarkers Prev. 2015 Jun;24(6):951-61. doi: 10.1158/1055-9965.EPI-14-1279-T. Epub 2015 Apr 8.

19.

Reproductive and hormone-related risk factors for epithelial ovarian cancer by histologic pathways, invasiveness and histologic subtypes: Results from the EPIC cohort.

Fortner RT, Ose J, Merritt MA, Schock H, Tjønneland A, Hansen L, Overvad K, Dossus L, Clavel-Chapelon F, Baglietto L, Boeing H, Trichopoulou A, Benetou V, Lagiou P, Agnoli C, Mattiello A, Masala G, Tumino R, Sacerdote C, Bueno-de-Mesquita HB, Onland-Moret NC, Peeters PH, Weiderpass E, Torhild Gram I, Duell EJ, Larrañaga N, Ardanaz E, Sánchez MJ, Chirlaque MD, Brändstedt J, Idahl A, Lundin E, Khaw KT, Wareham N, Travis RC, Rinaldi S, Romieu I, Gunter MJ, Riboli E, Kaaks R.

Int J Cancer. 2015 Sep 1;137(5):1196-208. doi: 10.1002/ijc.29471. Epub 2015 Feb 26.

20.

Early pregnancy IGF-I and placental GH and risk of epithelial ovarian cancer: A nested case-control study.

Schock H, Fortner RT, Surcel HM, Grankvist K, Pukkala E, Lehtinen M, Lundin E.

Int J Cancer. 2015 Jul 15;137(2):439-47. doi: 10.1002/ijc.29387. Epub 2014 Dec 17.

21.

Insulin-like growth factor I and risk of epithelial invasive ovarian cancer by tumour characteristics: results from the EPIC cohort.

Ose J, Fortner RT, Schock H, Peeters PH, Onland-Moret NC, Bueno-de-Mesquita HB, Weiderpass E, Gram IT, Overvad K, Tjonneland A, Dossus L, Fournier A, Baglietto L, Trichopoulou A, Benetou V, Trichopoulos D, Boeing H, Masala G, Krogh V, Matiello A, Tumino R, Popovic M, Obón-Santacana M, Larrañaga N, Ardanaz E, Sánchez MJ, Menéndez V, Chirlaque MD, Travis RC, Khaw KT, Brändstedt J, Idahl A, Lundin E, Rinaldi S, Kuhn E, Romieu I, Gunter MJ, Merritt MA, Riboli E, Kaaks R.

Br J Cancer. 2015 Jan 6;112(1):162-6. doi: 10.1038/bjc.2014.566. Epub 2014 Nov 4.

22.

Dietary intake of acrylamide and epithelial ovarian cancer risk in the european prospective investigation into cancer and nutrition (EPIC) cohort.

Obón-Santacana M, Peeters PH, Freisling H, Dossus L, Clavel-Chapelon F, Baglietto L, Schock H, Fortner RT, Boeing H, Tjønneland A, Olsen A, Overvad K, Menéndez V, Sanchez MJ, Larrañaga N, Huerta Castaño JM, Barricarte A, Khaw KT, Wareham N, Travis RC, Merritt MA, Trichopoulou A, Trichopoulos D, Orfanos P, Masala G, Sieri S, Tumino R, Vineis P, Mattiello A, Bueno-de-Mesquita HB, Onland-Moret NC, Wirfält E, Stocks T, Idahl A, Lundin E, Skeie G, Gram IT, Weiderpass E, Riboli E, Duell EJ.

Cancer Epidemiol Biomarkers Prev. 2015 Jan;24(1):291-7. doi: 10.1158/1055-9965.EPI-14-0636. Epub 2014 Oct 9.

23.

Early pregnancy sex steroids and maternal breast cancer: a nested case-control study.

Fortner RT, Schock H, Kaaks R, Lehtinen M, Pukkala E, Lakso HÅ, Tanner M, Kallio R, Joensuu H, Grankvist K, Zeleniuch-Jacquotte A, Toniolo P, Lundin E, Surcel HM.

Cancer Res. 2014 Dec 1;74(23):6958-67. doi: 10.1158/0008-5472.CAN-14-2150. Epub 2014 Oct 3.

24.

Early pregnancy sex steroids and maternal risk of epithelial ovarian cancer.

Schock H, Surcel HM, Zeleniuch-Jacquotte A, Grankvist K, Lakso HÅ, Fortner RT, Kaaks R, Pukkala E, Lehtinen M, Toniolo P, Lundin E.

Endocr Relat Cancer. 2014;21(6):831-44. doi: 10.1530/ERC-14-0282.

25.

Endogenous androgens and risk of epithelial invasive ovarian cancer by tumor characteristics in the European Prospective Investigation into Cancer and Nutrition.

Ose J, Fortner RT, Rinaldi S, Schock H, Overvad K, Tjonneland A, Hansen L, Dossus L, Fournier A, Baglietto L, Romieu I, Kuhn E, Boeing H, Trichopoulou A, Lagiou P, Trichopoulos D, Palli D, Masala G, Sieri S, Tumino R, Sacerdote C, Mattiello A, Ramon Quiros J, Obón-Santacana M, Larrañaga N, Chirlaque MD, Sánchez MJ, Barricarte A, Peeters PH, Bueno-de-Mesquita HB, Onland-Moret NC, Brändstedt J, Lundin E, Idahl A, Weiderpass E, Gram IT, Lund E, Kaw KT, Travis RC, Merritt MA, Gunther MJ, Riboli E, Kaaks R.

Int J Cancer. 2015 Jan 15;136(2):399-410. doi: 10.1002/ijc.29000. Epub 2014 Jun 16.

26.

Anti-Mullerian hormone and risk of invasive serous ovarian cancer.

Schock H, Lundin E, Vääräsmäki M, Grankvist K, Fry A, Dorgan JF, Pukkala E, Lehtinen M, Surcel HM, Lukanova A.

Cancer Causes Control. 2014 May;25(5):583-9. doi: 10.1007/s10552-014-0363-9. Epub 2014 Feb 22.

PMID:
24562905
27.

Free β-human chorionic gonadotropin, total human chorionic gonadotropin and maternal risk of breast cancer.

Toriola AT, Tolockiene E, Schock H, Surcel HM, Zeleniuch-Jacquotte A, Wadell G, Toniolo P, Lundin E, Grankvist K, Lukanova A.

Future Oncol. 2014 Feb;10(3):377-84. doi: 10.2217/fon.13.208.

28.

Premenopausal serum sex hormone levels in relation to breast cancer risk, overall and by hormone receptor status - results from the EPIC cohort.

Kaaks R, Tikk K, Sookthai D, Schock H, Johnson T, Tjønneland A, Olsen A, Overvad K, Clavel-Chapelon F, Dossus L, Baglietto L, Rinaldi S, Chajes V, Romieu I, Boeing H, Schütze M, Trichopoulou A, Lagiou P, Trichopoulos D, Palli D, Sieri S, Tumino R, Ricceri F, Mattiello A, Buckland G, Ramón Quirós J, Sánchez MJ, Amiano P, Chirlaque MD, Barricarte A, Bas Bueno-de-Mesquita H, van Gils CH, Peeters PH, Andersson A, Sund M, Weiderpass E, Khaw KT, Wareham N, Key TJ, Travis RC, Merritt MA, Gunter MJ, Riboli E, Lukanova A.

Int J Cancer. 2014 Apr 15;134(8):1947-57. doi: 10.1002/ijc.28528. Epub 2013 Oct 24.

29.

Prediagnostic plasma testosterone, sex hormone-binding globulin, IGF-I and hepatocellular carcinoma: etiological factors or risk markers?

Lukanova A, Becker S, Hüsing A, Schock H, Fedirko V, Trepo E, Trichopoulou A, Bamia C, Lagiou P, Benetou V, Trichopoulos D, Nöthlings U, Tjønneland A, Overvad K, Dossus L, Teucher B, Boeing H, Aleksandrova K, Palli D, Pala V, Panico S, Tumino R, Ricceri F, Bueno-de-Mesquita HB, Siersema PD, Peeters PH, Quiros JR, Duell EJ, Molina-Montes E, Chirlaque MD, Gurrea AB, Dorronsoro M, Lindkvist B, Johansen D, Werner M, Sund M, Khaw KT, Wareham N, Key TJ, Travis RC, Rinaldi S, Romieu I, Gunter MJ, Riboli E, Jenab M, Kaaks R.

Int J Cancer. 2014 Jan 1;134(1):164-73. doi: 10.1002/ijc.28342. Epub 2013 Aug 2.

30.

Determinants of maternal sex steroids during the first half of pregnancy.

Toriola AT, Vääräsmäki M, Lehtinen M, Zeleniuch-Jacquotte A, Lundin E, Rodgers KG, Lakso HA, Chen T, Schock H, Hallmans G, Pukkala E, Toniolo P, Grankvist K, Surcel HM, Lukanova A.

Obstet Gynecol. 2011 Nov;118(5):1029-36. doi: 10.1097/AOG.0b013e3182342b7f. Erratum in: Obstet Gynecol. 2012 Jan;119(1):186-7.

31.

Insulin-like growth factor-I and C-reactive protein during pregnancy and maternal risk of non-epithelial ovarian cancer: a nested case-control study.

Toriola AT, Surcel HM, Lundin E, Schock H, Grankvist K, Pukkala E, Chen T, Toniolo P, Lehtinen M, Zeleniuch-Jacquotte A, Lukanova A.

Cancer Causes Control. 2011 Nov;22(11):1607-11. doi: 10.1007/s10552-011-9828-2. Epub 2011 Aug 11.

PMID:
21833488
32.

Circulating insulin-like growth factor-I in pregnancy and maternal risk of breast cancer.

Toriola AT, Lundin E, Schock H, Grankvist K, Pukkala E, Chen T, Zeleniuch-Jacquotte A, Toniolo P, Lehtinen M, Surcel HM, Lukanova A.

Cancer Epidemiol Biomarkers Prev. 2011 Aug;20(8):1798-801. doi: 10.1158/1055-9965.EPI-11-0441. Epub 2011 Jun 15.

33.

Circulating estrogens and progesterone during primiparous pregnancies and risk of maternal breast cancer.

Lukanova A, Surcel HM, Lundin E, Kaasila M, Lakso HA, Schock H, Husing A, Kaaks R, Koskela P, Grankvist K, Pukkala E, Zeleniuch-Jacquotte A, Lehtinen M, Toniolo P.

Int J Cancer. 2012 Feb 15;130(4):910-20. doi: 10.1002/ijc.26070. Epub 2011 May 9.

34.

Association of serum 25-hydroxyvitamin D (25-OHD) concentrations with maternal sex steroids and IGF-1 hormones during pregnancy.

Toriola AT, Surcel HM, Husing A, Grankvist K, Lakso HA, Schock H, Lundin E, Lehtinen M, Lukanova A.

Cancer Causes Control. 2011 Jun;22(6):925-8. doi: 10.1007/s10552-011-9752-5. Epub 2011 Mar 9.

35.

Circulating sex steroids during pregnancy and maternal risk of non-epithelial ovarian cancer.

Chen T, Surcel HM, Lundin E, Kaasila M, Lakso HA, Schock H, Kaaks R, Koskela P, Grankvist K, Hallmans G, Pukkala E, Zeleniuch-Jacquotte A, Toniolo P, Lehtinen M, Lukanova A.

Cancer Epidemiol Biomarkers Prev. 2011 Feb;20(2):324-36. doi: 10.1158/1055-9965.EPI-10-0857. Epub 2010 Dec 21.

36.

Human chorionic gonadotropin in pregnancy and maternal risk of breast cancer.

Toniolo P, Grankvist K, Wulff M, Chen T, Johansson R, Schock H, Lenner P, Hallmans G, Lehtinen M, Kaaks R, Wadell G, Zeleniuch-Jacquotte A, Lundin E, Lukanova A.

Cancer Res. 2010 Sep 1;70(17):6779-86. doi: 10.1158/0008-5472.CAN-09-4622. Epub 2010 Aug 16.

37.

Maternal hormones during early pregnancy: a cross-sectional study.

Chen T, Lundin E, Grankvist K, Zeleniuch-Jacquotte A, Wulff M, Afanasyeva Y, Schock H, Johansson R, Lenner P, Hallmans G, Wadell G, Toniolo P, Lukanova A.

Cancer Causes Control. 2010 May;21(5):719-27. doi: 10.1007/s10552-009-9500-2. Epub 2010 Jan 19.

38.

IGF-I during primiparous pregnancy and maternal risk of breast cancer.

Chen T, Lukanova A, Grankvist K, Zeleniuch-Jacquotte A, Wulff M, Johansson R, Schock H, Lenner P, Hallmans G, Wadell G, Toniolo P, Lundin E.

Breast Cancer Res Treat. 2010 May;121(1):169-75. doi: 10.1007/s10549-009-0519-6. Epub 2009 Sep 2.

39.

The use of gravity or manual-stress radiographs in the assessment of supination-external rotation fractures of the ankle.

Schock HJ, Pinzur M, Manion L, Stover M.

J Bone Joint Surg Br. 2007 Aug;89(8):1055-9.

PMID:
17785745
40.

Value of MR phase-contrast flow measurements for functional assessment of pulmonary arterial hypertension.

Ley S, Mereles D, Puderbach M, Gruenig E, Schöck H, Eichinger M, Ley-Zaporozhan J, Fink C, Kauczor HU.

Eur Radiol. 2007 Jul;17(7):1892-7. Epub 2007 Jan 16.

PMID:
17225131
41.

Expression of androgen-binding protein (ABP) in human cardiac myocytes.

Schock HW, Herbert Z, Sigusch H, Figulla HR, Jirikowski GF, Lotze U.

Horm Metab Res. 2006 Apr;38(4):225-9.

PMID:
16700002
42.

Why is the fuel economy of a car better in the summer ?

Schock H.

Sci Am. 2004 Sep;291(3):122. No abstract available.

PMID:
15376763
43.

Gender differences in muscular protection of the knee in torsion in size-matched athletes.

Wojtys EM, Huston LJ, Schock HJ, Boylan JP, Ashton-Miller JA.

J Bone Joint Surg Am. 2003 May;85(5):782-9.

PMID:
12728025
44.

Plasmid DNA vaccines: assay for integration into host genomic DNA.

Ledwith BJ, Manam S, Troilo PJ, Barnum AB, Pauley CJ, Griffiths TG 2nd, Harper LB, Schock HB, Zhang H, Faris JE, Way PA, Beare CM, Bagdon WJ, Nichols WW.

Dev Biol (Basel). 2000;104:33-43.

PMID:
11713822
45.

An alternate binding site for the P1-P3 group of a class of potent HIV-1 protease inhibitors as a result of concerted structural change in the 80s loop of the protease.

Munshi S, Chen Z, Yan Y, Li Y, Olsen DB, Schock HB, Galvin BB, Dorsey B, Kuo LC.

Acta Crystallogr D Biol Crystallogr. 2000 Apr;56(Pt 4):381-8.

PMID:
10739910
46.

Non-active site changes elicit broad-based cross-resistance of the HIV-1 protease to inhibitors.

Olsen DB, Stahlhut MW, Rutkowski CA, Schock HB, vanOlden AL, Kuo LC.

J Biol Chem. 1999 Aug 20;274(34):23699-701.

47.

Therapeutic effects of nitric oxide inhibition during experimental fecal peritonitis: role of interleukin-10 and monocyte chemoattractant protein 1.

Hogaboam CM, Steinhauser ML, Schock H, Lukacs N, Strieter RM, Standiford T, Kunkel SL.

Infect Immun. 1998 Feb;66(2):650-5.

49.

Stem cell factor (c-kit ligand) influences eosinophil recruitment and histamine levels in allergic airway inflammation.

Lukacs NW, Strieter RM, Lincoln PM, Brownell E, Pullen DM, Schock HJ, Chensue SW, Taub DD, Kunkel SL.

J Immunol. 1996 May 15;156(10):3945-51.

PMID:
8621935
50.

Supplemental Content

Loading ...
Support Center